{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T11:21:10Z","timestamp":1764588070648,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To study the incidence of vancomycin-associated acute kidney injury (VA-AKI) in Hong Kong and identify risk factors for VA-AKI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Patients with vancomycin prescription and blood level measurement in 2012\u20132016 were identified using the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System. Acute kidney injury was defined using KDIGO criteria. Patients without creatinine measurements, steady-state trough vancomycin level or who had vancomycin treatment &lt;\u20093\u2009days were excluded. Results were analyzed using SPSS version 22.0. Logistic regression was used to identify the predictors for VA-AKI. Odds ratio and 95% confidence interval were estimated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One thousand four hundred fifty patients were identified as VA-AKI from 12,758 records in Hong Kong in 2012\u20132016. The incidence was respectively 10.6, 10.9, 11.3, 12.2, 11.2% from 2012 to 2016. The incidence of VA-AKI was 16.3, 12.2, 11.3 and 6.2% in patients aged 1\u201312, 12\u201360, elderly aged &gt;\u200960 and newborn and infants, respectively. Baseline creatinine, serum trough vancomycin level, systematic disease history including respiratory failure, hypertension, congestive heart failure, chronic renal failure, anemia and type II diabetes, and concomitant diuretics, piperacillin-tazobactam (PTZ) and meropenem prescription were significantly higher in VA-AKI patients older than 12\u2009years. Logistic regression showed that older age group, higher baseline creatinine, serum trough vancomycin level, respiratory failure, chronic renal failure and congestive heart failure, concomitant diuretics, PTZ and meropenem prescription, and longer hospital stay were all associated with increased risk of VA-AKI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The incidence of VA-AKI in Hong Kong is low but shows no decline. Patients with higher baseline creatinine, multi-organ diseases and multiple drugs administration should have their vancomycin level monitored to decrease the risk of VA-AKI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-020-1704-4","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T19:04:57Z","timestamp":1580756697000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Vancomycin-associated acute kidney injury in Hong Kong in 2012\u20132016"],"prefix":"10.1186","volume":"21","author":[{"given":"Xuzhen","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Fung","family":"Tsoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-7363","authenticated-orcid":false,"given":"Bernard M. Y.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"3","key":"1704_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285\u201392.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"1704_CR2","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1093\/jac\/dkw254","volume":"71","author":"ZK Ye","year":"2016","unstructured":"Ye ZK, Chen YL, Chen K, et al. Therapeutic drug monitoring of vancomycin: a guideline of the division of therapeutic drug monitoring, Chinese Pharmacological Society. J Antimicrob Chemother. 2016;71(11):3020\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 4","key":"1704_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1469-0691.12450","volume":"20","author":"J Chastre","year":"2014","unstructured":"Chastre J, Blasi F, Masterton RG, Rello J, Torres A, Welte T. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20(Suppl 4):19\u201336.","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"1704_CR4","first-page":"1","volume":"26","author":"J Mensa","year":"2013","unstructured":"Mensa J, Soriano A, Llinares P, et al. Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus. Rev Esp Quimioter. 2013;26(Suppl 1):1\u201384.","journal-title":"Rev Esp Quimioter"},{"issue":"3","key":"1704_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the society of infectious diseases pharmacists. Clin Infect Dis. 2009;49(3):325\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1704_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","volume":"102","author":"EJ Filippone","year":"2017","unstructured":"Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of Vancomycin. Clin Pharmacol Ther. 2017;102(3):459\u201369.","journal-title":"Clin Pharmacol Ther"},{"issue":"9987","key":"1704_CR7","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/S0140-6736(15)60126-X","volume":"385","author":"RL Mehta","year":"2015","unstructured":"Mehta RL, Cerd\u00e1 J, Burdmann EA, et al. International society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. 2015;385(9987):2616\u201343.","journal-title":"Lancet"},{"issue":"6","key":"1704_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/01.ccx.0000247448.94252.5a","volume":"12","author":"S Uchino","year":"2006","unstructured":"Uchino S. The epidemiology of acute renal failure in the world. Curr Opin Crit Care. 2006;12(6):538\u201343.","journal-title":"Curr Opin Crit Care"},{"issue":"1","key":"1704_CR9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijantimicag.2010.09.003","volume":"37","author":"JH You","year":"2011","unstructured":"You JH, Chow SS, Lui JW, Ip M. New target concentrations for vancomycin in Hong Kong. Int J Antimicrob Agents. 2011;37(1):83\u20134.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"1704_CR10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.30277","volume":"63","author":"CC Mok","year":"2011","unstructured":"Mok CC, Kwok CL, Ho LY, Chan PT, Yip SF. Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China. Arthritis Rheum. 2011;63(5):1182\u20139.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1704_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/pds.4156","volume":"26","author":"CW Sing","year":"2017","unstructured":"Sing CW, Wong IC, Cheung BM, Chan JC, Chu JK, Cheung CL. Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study. Pharmacoepidemiol Drug Saf. 2017;26(3):248\u201355.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"1704_CR12","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1093\/ndt\/gfs375","volume":"27","author":"D Fliser","year":"2012","unstructured":"Ad-hoc working group of E, Fliser D, Laville M, et al. A European renal best practice (ERBP) position statement on the kidney disease improving global outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27(12):4263\u201372.","journal-title":"Nephrol Dial Transplant"},{"key":"1704_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijid.2015.06.025","volume":"37","author":"MH Dong","year":"2015","unstructured":"Dong MH, Wang JW, Wu Y, Chen BY, Yu M, Wen AD. Evaluation of body weight-based vancomycin therapy and the incidence of nephrotoxicity: a retrospective study in the northwest of China. Int J Infect Dis. 2015;37:125\u20138.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"1704_CR14","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1111\/jcpt.12437","volume":"41","author":"WX Wei","year":"2016","unstructured":"Wei WX, Qin XL, Cheng DH, Lu H, Liu TT. Retrospective analysis of vancomycin treatment outcomes in Chinese paediatric patients with suspected gram-positive infection. J Clin Pharm Ther. 2016;41(6):650\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"5\u20136","key":"1704_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000381783","volume":"95","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yin Y, Liu XZ, et al. Retrospective analysis of Vancomycin nephrotoxicity in elderly Chinese patients. Pharmacology. 2015;95(5\u20136):279\u201384.","journal-title":"Pharmacology"},{"issue":"8","key":"1704_CR16","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1440-1797.2011.01488.x","volume":"16","author":"WC Shen","year":"2011","unstructured":"Shen WC, Chiang YC, Chen HY, et al. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Nephrology (Carlton). 2011;16(8):697\u2013703.","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"1704_CR17","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107\u201315.","journal-title":"Clin Ther"},{"issue":"2","key":"1704_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.12788\/jhm.2684","volume":"12","author":"WC Rutter","year":"2017","unstructured":"Rutter WC, Burgess DR, Talbert JC, Burgess DS. Acute kidney injury in patients treated with vancomycin and piperacillin-tazobactam: a retrospective cohort analysis. J Hosp Med. 2017;12(2):77\u201382.","journal-title":"J Hosp Med"},{"issue":"3","key":"1704_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/QCO.0000000000000263","volume":"29","author":"JM Lestner","year":"2016","unstructured":"Lestner JM, Hill LF, Heath PT, Sharland M. Vancomycin toxicity in neonates: a review of the evidence. Curr Opin Infect Dis. 2016;29(3):237\u201347.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"1704_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","volume":"158","author":"S McKamy","year":"2011","unstructured":"McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children. J Pediatr. 2011;158(3):422\u20136.","journal-title":"J Pediatr"},{"issue":"2","key":"1704_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ped.13463","volume":"60","author":"M Abouelkheir","year":"2018","unstructured":"Abouelkheir M, Alsubaie S. Pediatric acute kidney injury induced by concomitant vancomycin and piperacillin-tazobactam. Pediatr Int. 2018;60(2):136\u201341.","journal-title":"Pediatr Int"},{"issue":"11","key":"1704_CR22","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/1060028017720946","volume":"51","author":"YC Choi","year":"2017","unstructured":"Choi YC, Saw S, Soliman D, et al. Intravenous Vancomycin associated with the development of nephrotoxicity in patients with class III obesity. Ann Pharmacother. 2017;51(11):937\u201344.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1704_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12887-017-0777-0","volume":"17","author":"V Bhargava","year":"2017","unstructured":"Bhargava V, Malloy M, Fonseca R. The association between vancomycin trough concentrations and acute kidney injury in the neonatal intensive care unit. BMC Pediatr. 2017;17(1):50.","journal-title":"BMC Pediatr"},{"key":"1704_CR24","doi-asserted-by":"crossref","unstructured":"Conway EL, Sellick JA, Horey A, et al. Decreased mortality in patients prescribed vancomycin after implementation of antimicrobial stewardship program. Am J Infect Control. 2017;45(11):1194\u20137.","DOI":"10.1016\/j.ajic.2017.06.012"},{"issue":"2","key":"1704_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40121-013-0022-6","volume":"2","author":"JJ Carreno","year":"2013","unstructured":"Carreno JJ, Jaworski A, Kenney RM, Davis SL. Comparative incidence of nephrotoxicity by age group among adult patients receiving Vancomycin. Infect Dis Ther. 2013;2(2):201\u20138.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"1704_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1574886311666161024164859","volume":"12","author":"CK Mellen","year":"2017","unstructured":"Mellen CK, Ryba JE, Rindone JP. Does Piperacillin-Tazobactam increase the risk of nephrotoxicity when used with Vancomycin: a meta-analysis of observational trials. Curr Drug Saf. 2017;12(1):62\u20136.","journal-title":"Curr Drug Saf"},{"key":"1704_CR27","doi-asserted-by":"crossref","unstructured":"Gomes DM, Smotherman C, Birch A, et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.Pharmacotherapy. 2014;34(7):662\u20139.","DOI":"10.1002\/phar.1428"},{"issue":"4","key":"1704_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1089\/jop.2010.0163","volume":"27","author":"RK Tang","year":"2011","unstructured":"Tang RK, Tse RK. Acute renal failure after topical fortified gentamicin and vancomycin eyedrops. J Ocul Pharmacol Ther. 2011;27(4):411\u20133.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"1704_CR29","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1128\/AAC.05344-11","volume":"56","author":"S Nambiar","year":"2012","unstructured":"Nambiar S, Madurawe RD, Zuk SM, et al. Product quality of parenteral vancomycin products in the United States. Antimicrob Agents Chemother. 2012;56(6):2819\u201323.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"1704_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1060028016673858","volume":"51","author":"JJ Carreno","year":"2017","unstructured":"Carreno JJ, Kenney RM, Divine G, Vazquez JA, Davis SL. Randomized controlled trial to determine the efficacy of early switch from Vancomycin to Vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP-NT). Ann Pharmacother. 2017;51(3):185\u201393.","journal-title":"Ann Pharmacother"},{"issue":"Suppl 4","key":"1704_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/nep.13450","volume":"23","author":"CC Szeto","year":"2018","unstructured":"Szeto CC. Perspectives on acute kidney injury strategy: Hong Kong. Nephrology (Carlton). 2018;23(Suppl 4):104\u20136.","journal-title":"Nephrology (Carlton)"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-1704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-020-1704-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-1704-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T01:24:15Z","timestamp":1612229055000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-1704-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-1704-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2020,2,3]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project has been approved by Institutional Review Board of the University of Hong Kong\/Hospital Authority Hong Kong West Cluster (HKU\/HA HKW IRB Reference Number: UW 19\u2013378). This is a retrospective study and all patients included were identified anonymously.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors all consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}